Cogstate LtdASX: CGS

Business Update - approval of Alzheimers therapeutic

· Issued by Cogstate Ltd

Filed with ASX · · 6 pages · English

Eisai Co., Ltd (Japan) and their development partner, Biogen Inc, have announced that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval for aducanumab (to be marketed as TM ADUHELM ) for the treatment of Alzheimer’s disease. A copy of the press release from Eisai Co. Ltd and Biogen Inc. is attached. The accelerated approval has been granted based on data from clinical tr

Cogstate Ltd on 6ix

Earlier from Cogstate

Later from Cogstate

All Cogstate news releases